Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Why do cancer drugs get such an easy ride?

× No keyword cloud information.

11 in total

1. The Tip of the Iceberg of Misleading Online Advertising Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".

Authors: Barbara Mintzes
Journal: Int J Health Policy Manag Date: 2016-02-18

2. A Multi-centric Bioequivalence Trial in Ph+ Chronic Myeloid Leukemia Patients to Assess Bioequivalence and Safety Evaluation of Generic Imatinib Mesylate 400 mg Tablets.

Authors: Rachna Arora; Manju Sharma; Tausif Monif; Sunil Iyer
Journal: Cancer Res Treat Date: 2016-02-12 Impact factor: 4.679

3. Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval?

Authors: Nicole Grössmann; Claudia Wild
Journal: ESMO Open Date: 2017-01-31

4. Social media as a tool for assessing patient perspectives on quality of life in metastatic melanoma: a feasibility study.

Authors: Amr Makady; Rachel R J Kalf; Bettina Ryll; Gilliosa Spurrier; Anthonius de Boer; Hans Hillege; Olaf H Klungel; Wim Goettsch
Journal: Health Qual Life Outcomes Date: 2018-11-29 Impact factor: 3.186

5. Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.

Authors: Huseyin Naci; Courtney Davis; Jelena Savović; Julian P T Higgins; Jonathan A C Sterne; Bishal Gyawali; Xochitl Romo-Sandoval; Nicola Handley; Christopher M Booth
Journal: BMJ Date: 2019-09-18

Review 6. Late translational research: putting forward a new model for developing new anti-cancer treatments that addresses the needs of patients and society.

Authors: Denis Lacombe; Jan Bogaerts; Bertrand Tombal; François Maignen; Leeza Osipienko; Richard Sullivan; Vassilis Golfinopoulos
Journal: Mol Oncol Date: 2019-01-19 Impact factor: 6.603

7. For Whom the Price Escalates: High Price and Uncertain Value of Cancer Drugs.

Authors: Gyeongseon Shin; Hye-Young Kwon; SeungJin Bae
Journal: Int J Environ Res Public Health Date: 2022-04-01 Impact factor: 3.390

8. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study.

Authors: Aaron S Kesselheim; Bo Wang; Jessica M Franklin; Jonathan J Darrow
Journal: BMJ Date: 2015-09-23

9. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014.

Authors: Anthony J Hatswell; Gianluca Baio; Jesse A Berlin; Alar Irs; Nick Freemantle
Journal: BMJ Open Date: 2016-06-30 Impact factor: 2.692

10. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.

Authors: Courtney Davis; Huseyin Naci; Evrim Gurpinar; Elita Poplavska; Ashlyn Pinto; Ajay Aggarwal
Journal: BMJ Date: 2017-10-04